Japanese researchers report promising results from an experimental therapy for Parkinson’s disease that involves implanting neurons made from reprogrammed stem cells into the brain.
You are here
Coverage of the latest news and updates from the field of stem cells.
A new study in mice, conducted by researchers at the University of California, Irvine, details a potential therapeutic strategy that uses stem cells to promote recovery of motor activity after spinal cord injury.
The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor.
ViraCyte LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, reported positive data from a Phase 2 clinical trial evaluating its T-cell immunotherapy product, Viralym-M.
A new study from the Children’s Medical Center Research Institute (CRI) at the University of Texas Southwestern has found that stem cells take up unusually high levels of vitamin C, which then regulates their function and suppresses the development of leukemia.
A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School of Medicine.
Gastric carcinoma is one of the most common causes of cancer-related deaths, primarily because most patients present at an advanced stage of the disease. The main cause of this cancer is the bacterium Helicobacter pylori, which chronically infects around half of all humans.
Scientists at the University of Oxford have developed a new method to 3D-print laboratory-grown cells to form living structures.
A team of University of Toronto engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.
It’s a cancer of the plasma cells, which normally make an array of antibodies that protect us from infection.With multiple myeloma, the cells start primarily producing instead a singular product, called a monoclonal antibody or M spike, that leaves patients vulnerable for serious infections such